Momenta Pharmaceuticals Inc MNTA:NASDAQ

Last Price$11.94Cboe Real-Time Last Sale as of 3:13PM ET 6/24/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.30(2.45%)
Bid (Size)$11.94 (200)
Ask (Size)$11.96 (100)
Day Low / High$11.89 - 12.27
Volume165.1 K

View Biotechnology IndustryPeer Comparison as of 06/24/2019


Momenta Pharmaceuticals Inc ( NASDAQ )

Price: $11.94
Change: -0.30 (2.45%)
Volume: 165.1 K
3:13PM ET 6/24/2019

Intrexon Corp ( NASDAQ )

Price: $7.26
Change: -0.31 (4.10%)
Volume: 1.2 M
3:12PM ET 6/24/2019

OPKO Health Inc ( NASDAQ )

Price: $2.04
Change: +0.03 (1.49%)
Volume: 1.1 M
3:10PM ET 6/24/2019

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A

Aimmune Therapeutics Inc ( NASDAQ )

Price: $19.61
Change: -0.39 (1.95%)
Volume: 187.9 K
3:13PM ET 6/24/2019

Read more news Recent News

Insider Trends: Selling By Insiders Endures at Momenta Pharmaceuticals
4:16PM ET 6/21/2019 MT Newswires

Dr Anthony M Manning, Chief Scientific Officer, sold 39,433 shares in Momenta Pharmaceuticals (MNTA) for $512,629 on Jun 20, 2019. After the Form 4 filing...

Amphastar Pharmaceuticals to Receive $59.9 Mln from Lawsuit Settlement With Momenta, Sandoz
6:57AM ET 6/19/2019 MT Newswires

Amphastar Pharmaceuticals (AMPH) said Wednesday it has signed a settlement agreement with Momenta Pharmaceuticals Inc. (MNTA) and Sandoz Inc. to dismiss a...

Momenta Pharmaceuticals Misses Q1 Loss Per Share, Revenue Estimates
3:04PM ET 5/02/2019 MT Newswires

Momenta Pharmaceuticals (MNTA) said Thursday that its Q1 net loss was $44.8 million, or a $0.46 loss per share, compared to the year-ago net loss of $47.6...

Insider Trends: Insider 90-Day Selling Trend Extended at Momenta Pharmaceuticals
4:09PM ET 5/01/2019 MT Newswires

Alejandra Carvajal, Chief Legal Officer, on Apr 29, 2019, executed a sale of 10,384 shares in Momenta Pharmaceuticals (MNTA) for $153,372. The sale of...

Company Profile

Business DescriptionMomenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. View company web site for more details
Address301 Binney Street
Cambridge, Massachusetts 02142
Number of Employees131
Recent SEC Filing06/21/20198-K
President, Chief Executive Officer & DirectorCraig A. Wheeler
Treasurer, Chief Financial & Accounting OfficerMichelle Robertson
Chief Scientific OfficerAnthony M. Manning
Chief Medical Officer & Senior VP-DevelopmentSantiago Arroyo

Company Highlights

Price Open$12.18
Previous Close$12.24
52 Week Range$9.55 - 32.20
Market Capitalization$1.2 B
Shares Outstanding98.6 M
SectorHealth Technology
Next Earnings Announcement08/08/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.96
Beta vs. S&P 500N/A
Revenue$75.6 M
Net Profit Margin-231.49%
Return on Equity-49.02%

Analyst Ratings as of 06/14/2019

Consensus RecommendationConsensus Icon
Powered by Factset